Pharmacokinetics and immunogenicity
The plasma concentrations of pamiparib and tislelizumab indicated that the combination of the two study drugs had no impact on the pharmacokinetic profile of either drug (data not shown). The overall prevalence and incidence of ADAs for tislelizumab were low (3.3% [6/180 patients in the overall population], and 3.2% [5/156 patients in the ADA evaluable population], respectively), and no patients tested positive for neutralising antibodies.